指南与共识骨软组织肉瘤与黑色素瘤支持与姑息治疗

卡波西肉瘤的诊断与治疗:欧洲共识跨学科指南(EDF/EADO/EORTC)

Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC).
指南 / 共识 · Eur J Cancer · 2019-05-13

该欧洲共识指南由EDF/EADO/EORTC制定,针对卡波西肉瘤(KS)的四种临床亚型,提出诊断主要基于临床特征并经组织学与免疫组化确认;治疗目标为控制疾病,局部治疗用于局限病变,系统治疗用于局部侵袭性广泛和播散性KS,推荐一线药物为聚乙二醇脂质体多柔比星(PLD)和紫杉醇。

要点

  • KS诊断主要基于临床特征,经组织学与免疫组化确认。
  • 局限病变可采用放疗、病灶内化疗、电化疗或局部免疫调节剂。
  • 系统治疗一线推荐PLD或紫杉醇,用于局部侵袭性广泛和播散性KS。

核心结论

  • KS管理应致力于实现疾病控制,治疗选择取决于临床亚型、病变范围与严重程度。

研究设计与样本

  • 欧洲共识跨学科指南,由EDF/EADO/EORTC制定。

主要发现

  • KS是淋巴内皮来源细胞的多灶性肿瘤,与人疱疹病毒8型感染相关。
  • 区分经典型、地方型、HIV阳性患者的流行型及医源型四种临床亚型。
  • 经典型通常呈惰性行为与慢性演变,医源型或流行型可出现更严重形式。
  • 局部病变有多种局部疗法,但无随机试验比较。
  • 放疗、病灶内化疗和电化疗有高缓解率,局部治疗可用咪喹莫特或局部9-顺式维A酸。

关键数值与推荐

  • 系统治疗推荐一线药物为聚乙二醇脂质体多柔比星(PLD)和紫杉醇,用于局部侵袭性广泛和播散性KS。
  • 经典型KS中,年轻患者推荐一线药物为PLD或低剂量干扰素-α。
  • AIDS相关KS中,联合抗逆转录病毒治疗是首选治疗,仅在广泛病变及预防和治疗免疫重建炎症综合征时需特异性系统治疗。
  • 移植后KS中,采用减量免疫抑制治疗并换用哺乳动物雷帕霉素靶蛋白(m-TOR)抑制剂。
  • KS患者随访方案取决于疾病的侵袭性。

临床怎么用

  • 局限病变可选用放疗、病灶内化疗、电化疗、咪喹莫特或局部9-顺式维A酸。
  • 局部侵袭性广泛和播散性KS系统治疗推荐一线使用PLD或紫杉醇。
  • 经典型KS年轻患者系统治疗推荐一线使用PLD或低剂量干扰素-α。
  • AIDS相关KS首选联合抗逆转录病毒治疗,广泛病变及免疫重建炎症综合征时加用特异性系统治疗。
  • 移植后KS采用减量免疫抑制并换用m-TOR抑制剂,随访方案依疾病侵袭性而定。

局限性

  • 局部疗法无随机试验比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Kaposi's sarcoma (KS) is a multifocal neoplasm of lymphatic endothelium-derived cells infected with human herpesvirus 8. Four clinical subtypes are distinguished: the classic, the endemic, the epidemic subtype in HIV positive patients and the iatrogenic subtype. The diagnosis is primarily based on clinical features and confirmation by histology with immunohistochemistry. Cutaneous distribution and severity, mucosal, nodal and visceral involvement depend on the type of KS with in general indolent behaviour and chronic evolution in the classic subtype and the more severe forms in iatrogenic or epidemic subtypes. Management should aim at achieving disease control. For localised lesions, several local therapies have been developed without randomised trial comparisons. Radiotherapy, intralesional chemotherapies and electrochemotherapy have high response rates. Topical treatments-imiquimod or topical 9-cis-retinoid acid-can also be used. Systemic treatments are reserved for locally aggressive extensive and disseminated KS: the recommended first-line agents are pegylated liposomal doxorubicin (PLD) and paclitaxel. In CKS, PLD or low-dose interferon-alfa are the recommended first-line agents in younger patients. In AIDS-related KS, combination antiretroviral therapy is the first treatment option; specific systemic treatment is needed only in case of extensive disease and in the prevention and treatment of immune reconstitution inflammatory syndrome. In post-transplant KS, tapering down immunosuppressive therapy and switching to mammalian target of rapamycin (m-TOR) inhibitors are used. Follow-up schedules for patients with KS disease depend on aggressiveness of the disease.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lebbe C, Garbe C, Stratigos AJ, et al. Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). Eur J Cancer. 2019. PMID: 31096150. doi:10.1016/j.ejca.2018.12.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。